

METAFOR™ TECHNICAL SPECIFICATIONS

STENT	
Stent Material	: Cobalt Chromium L605
Strut Thickness	: 65 µm (0.065 mm or 0.0026")
Stent Diameters (mm)	: 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 4.50
Stent Lengths (mm)	: 8, 13, 16, 19, 24, 29, 32, 37, 40, 44, 48
Mean Recoil	: 3%
Mean Foreshortening	: 0.29%

DRUG / POLYMER	
Drug	: Sirolimus
Equivalent Drug Dose	: 1.25 µg / mm ²
Polymer	: Biodegradable and Biocompatible

DELIVERY SYSTEM	
Delivery System	: Rapid Exchange
Stent Diameter	: Crossing Profile
mm	mm / inches
2.00	0.83 / 0.033"
2.25	0.85 / 0.033"
2.50	0.91 / 0.036"
2.75	0.98 / 0.039"
3.00	0.99 / 0.039"
3.50	1.06 / 0.042"
4.00	1.16 / 0.046"
4.50	1.19 / 0.047"
Nominal Pressure	: 9 atm
Rated Burst Pressure	: 14 / 16 atm depending upon size and length of stent (Refer IFU for more details)
Balloon Overhang	: < 0.5 mm
Shaft Outer Diameter	: Proximal 1.95 - 1.98 F (2.13 F for stent lengths 44 mm and 48 mm) Distal 2.7 F (2.4 F for diameter 2.00 mm)
Radiopaque Markers	: 2 - Platinum / Iridium
Usable Catheter Length	: 140 - 142 cm
Guide Catheter Compatibility	: 5 F (Min. I. D. 0.056" / 1.42 mm)
Max. Guidewire	: 0.014" (0.36 mm)

METAFOR™ ORDERING INFORMATION

Diameters / Lengths	8 mm	13 mm	16 mm	19 mm	24 mm	29 mm
2.00 mm	-	MTR20013	MTR20016	MTR20019	MTR20024	-
2.25 mm	MTR22508	MTR22513	MTR22516	MTR22519	MTR22524	MTR22529
2.50 mm	MTR25008	MTR25013	MTR25016	MTR25019	MTR25024	MTR25029
2.75 mm	MTR27508	MTR27513	MTR27516	MTR27519	MTR27524	MTR27529
3.00 mm	MTR30008	MTR30013	MTR30016	MTR30019	MTR30024	MTR30029
3.50 mm	MTR35008	MTR35013	MTR35016	MTR35019	MTR35024	MTR35029
4.00 mm	MTR40008	MTR40013	MTR40016	MTR40019	MTR40024	MTR40029
4.50 mm	MTR45008	MTR45013	MTR45016	MTR45019	MTR45024	MTR45029

Diameters / Lengths	32 mm	37 mm	40 mm	44 mm	48 mm
2.00 mm	-	-	-	-	-
2.25 mm	MTR22532	MTR22537	MTR22540	-	-
2.50 mm	MTR25032	MTR25037	MTR25040	MTR25044	MTR25048
2.75 mm	MTR27532	MTR27537	MTR27540	MTR27544	MTR27548
3.00 mm	MTR30032	MTR30037	MTR30040	MTR30044	MTR30048
3.50 mm	MTR35032	MTR35037	MTR35040	MTR35044	MTR35048
4.00 mm	MTR40032	MTR40037	MTR40040	-	-
4.50 mm	MTR45032	MTR45037	MTR45040	-	-

Meril

Meril Life Sciences Pvt. Ltd.
Survey No. 135/139, Bilakhia House,
Muktanand Marg, Chala,
Vapi 396 191,
Gujarat, India.
T +91 260 305 2100
F +91 260 305 2125

Meril, Inc.
116, Village Boulevard, Suite 200,
Princeton, NJ 08540, USA.
T +1 609 951 2287
F +1 609 520 1702

Meril South America
Doc Med LTDA
Al. dos Tupiniquins,
1079 - Cep: 04077-003 - Moema,
Sao Paulo, Brazil.
T +55 11 3624 5935
F +55 11 3624 5936

Meril GmbH.
Bornheimer Strasse 135-137,
D-53119 Bonn,
Germany.
T +49 228 7100 4000
F +49 228 7100 4001

Meril Tibbi Cihazlar
İmalat Ve Ticaret A. S.
6, Mimar sinan Mah.,
Çavusbasi Cad. Özde Sok.
Aydin Eksi İls Merkezi Kat:1
Cekmekoy / Istanbul, Turkey.
T +90 53 2272 5172

E askinfo@merillife.com
W www.merillife.com

Metafor™ is not approved
& not available for sale in USA.
Metafor™ is registered trademark
of Meril Life Sciences Pvt. Ltd.

METAFOR™

Sirolimus Eluting Coronary Stent System


Meril

METAFOR™

Sirolimus Eluting Coronary Stent System


Stent Architecture

- Primary stent platform for Metafor™ SES is NexGen™ Cobalt Chromium Coronary Stent System.
- Unique cell design comprising of an intelligent mix of open and closed cells.
- Low strut thickness 65 µm cobalt chromium L605 coupled with variable strut width composition results in a structure which provides optimal radial strength with flexibility.




Anti-proliferative Drug - Sirolimus

- It is known that Sirolimus inhibits T-lymphocyte activation and smooth muscle and endothelial cell proliferation in response to cytokine and growth factor stimulation. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12). The sirolimus – FKBP 12 complex binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), leading to inhibition of cell cycle progression from the G1 to the S phase.



Biodegradable Polymer base

- Metafor™ SES has a unique biocompatible and biodegradable polymer base.
- The polymer elutes almost simultaneously as the drug thus minimizing the propensity for a polymer related inflammation.



Drug Release Platform

- Metafor™ SES uses a validated formulation of low dose sirolimus (1.25 µg/mm²) timed to elute in ~ 30 days from a biodegradable polymer base which degrades simultaneously.
- Specially developed spray coating technology results in a uniform, homogeneous coating ensuring coating integrity.

